{"name":"Mundipharma K.K.","slug":"mundipharma-k-k","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Buprenorphine Transdermal System","genericName":"Buprenorphine Transdermal System","slug":"buprenorphine-transdermal-system","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pralatrexate injection","genericName":"Pralatrexate injection","slug":"pralatrexate-injection","indication":"Peripheral T-cell lymphoma (PTCL)","status":"phase_3"}]}],"pipeline":[{"name":"Buprenorphine Transdermal System","genericName":"Buprenorphine Transdermal System","slug":"buprenorphine-transdermal-system","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pralatrexate injection","genericName":"Pralatrexate injection","slug":"pralatrexate-injection","phase":"phase_3","mechanism":"Pralatrexate is a folate analog that inhibits dihydrofolate reductase and other folate-dependent enzymes, disrupting DNA synthesis and cell division in rapidly dividing cells.","indications":["Peripheral T-cell lymphoma (PTCL)","Relapsed or refractory T-cell lymphomas"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHaUwteHZ4STgxaEpMWWRKT3I2ZE1sSFRMZWJYdm1aUG1TS3VVbFBxWUZKV05xRHBxRzc0U25WLURIVVZyZFdfaHUzYlV6Ym5KMDdaWUh4NXpRQlUzOWFB?oc=5","date":"2025-02-17","type":"trial","source":"Nature","summary":"Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study | Leukemia - Nature","headline":"Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study | Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPM1lmZFdBUWhIRElmdnJseG1tRkxJaXc4Z1FUZkFheHBxQTNocXNtRF83RzZILXNnVzBndi1RU1oyMDljSXRVVDRtZGJ1cjdadGlDZDI0VmN1cE5oM05fOFd6dkgtQlFtbTV0T3RyUFFta3hpd21HRDlDZTcyMHkyMmNieTlkc3oxXzVnc3VlWmVJZmhFang0WEpiVl9qX016T3lSUmVVR1RWTFpaaEJlWkkwNDNpS2lEWVc4?oc=5","date":"2019-05-29","type":"pipeline","source":"The Week","summary":"Purdue Pharma's international wing has been implicated in an opioid corruption scandal in Italy - The Week","headline":"Purdue Pharma's international wing has been implicated in an opioid corruption scandal in Italy","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}